🇺🇸 FDA
Pipeline program

Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

VS-6766-301

Phase 3 small_molecule active

Quick answer

Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf for Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) is a Phase 3 program (small_molecule) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Vera Therapeutics
Indication
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials